The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1597
May 4, 2020
View Complete Issue         Table of Contents 2019 
Issue 1597
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
In Brief: Neuropsychiatric Events with Montelukast
May 4, 2020 (Issue: 1597)
The FDA is requiring stronger warnings in the labeling of the leukotriene receptor antagonist montelukast (Singulair, and generics) about the risk of suicidal behavior and other serious neuropsychiatric events associated with its use.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1597
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.